Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-04-29 Legal Proceedings Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Truqap recommended for EU breast cancer approval
Legal Proceedings Report Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca PLC, dated April 29, 2024. The content details a positive opinion from the European Medicines Agency's CHMP regarding the recommendation for approval of the drug combination Truqap plus Faslodex for breast cancer treatment. This is a specific, time-sensitive announcement of a regulatory/clinical development milestone, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal regulatory announcement disseminated via RNS, and it doesn't fit the specific definitions for DVA, DIV, or MANG, the most appropriate classification is RNS (Regulatory Filings), which serves as the general category for such official market communications that are not otherwise specified.
2024-04-29 English
Enhertu improved PFS in HER2-low and ultralow
Earnings Release Classification · 1% confidence The document is identified by the RNS Number (3073M) and the date (29 April 2024), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content describes positive high-level results from the DESTINY-Breast06 Phase III trial for the drug Enhertu, including statistical significance in progression-free survival. This is a material announcement of clinical trial data, which is typically released as an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement of clinical trial results, it fits best under the 'Earnings Release' category (ER) if it were quarterly results, but given the context of a major clinical trial update that is not explicitly labeled as an earnings report, and the presence of the RNS header, the most appropriate general category for a significant, non-standard regulatory update is 'Regulatory Filings' (RNS), as it is a broad category for material news disseminated via RNS that doesn't fit other specific financial report types (like 10-K or IR). However, major clinical trial updates often accompany or substitute for an Earnings Release (ER) when they contain significant financial/operational news. Given the structure (RNS header, announcement of trial results, statement that data will be presented at a forthcoming meeting), it functions as a major corporate news announcement. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical trial result announcement, 'RNS' is the most accurate fit as a general regulatory disclosure. Q2 2024
2024-04-29 English
1ST QUARTER RESULTS
Foreign Filer Report
2024-04-25 English
1st Quarter Results
Earnings Release Classification · 1% confidence The document is dated April 25, 2024, and explicitly states 'Q1 2024 results' and provides detailed financial tables for 'Q1 2024'. It includes key performance indicators (Revenue, EPS) and management commentary typical of a periodic financial disclosure. Since it covers a period shorter than a year (the first quarter), it fits the definition of an Interim/Quarterly Report (IR). It is not a full Annual Report (10-K), a brief announcement of results (ER), or a transcript (CT). The presence of RNS Number and the date format suggest it was released via a regulatory news service, but the content itself is the comprehensive quarterly financial report, making IR the most accurate classification over the general RNS fallback. Q1 2024
2024-04-25 English
Special Business Approved at AGM
AGM Information Classification · 1% confidence The document explicitly details the 'RESOLUTIONS' passed at an 'Annual General Meeting' (AGM) of AstraZeneca PLC held on 'Thursday 11 April 2024'. The content consists of specific resolutions (8, 10, 11, 12, 13, 14) concerning share plans, allotment authorities under the Companies Act 2006, and share purchases. This content is the official record of the decisions made during the AGM, which aligns perfectly with the definition of 'AGM Information' (AGM-R). It is not a general earnings release (ER), a full annual report (10-K), or a proxy statement (PSI), but the outcome of the meeting itself.
2024-04-12 English
RESULT OF AGM
Foreign Filer Report
2024-04-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.